The leading brand in microbiological testing makes another breakthrough! Qixin Technology announces its efforts to build a regenerative medical supply chain
Taiwan’s leading brand of biomedical testing, Qixin Technology, announced that it will fully expand its “cell and gene therapy technology” business unit to fully provide customized products and services for cell therapy technology. Qixin Technology, Taiwan’s first IVD-GMP (Good Manufacturing Practice) culture medium manufacturing factory certified, has dual roles in channel marketing, R&D and manufacturing. It has provided testing products and services for more than 40 years, helping to improve Taiwan’s biotech medical testing technology. With a wide range of services, it is the driving force behind Taiwan’s biotech and pharmaceutical industry. Not only does it have its own brand CMP®, but it has established more than 600 finished culture media and diagnostic reagent products that meet international certifications. It has also successfully integrated with many well-known international heavyweight brands, including BD Biddy, which is affiliated with the global benchmark medical company and Thermo Fisher- The company’s diagnostics department MBD; international biomedical leaders Lonza and Sartorius, etc., are partners of many international cell therapy innovative technology companies.
Regenerative medicine breaks through cell therapy to show new ideas
At the expansion development press conference, Qishin Technology announced that the new business scope of “regenerative medicine” will be expanded to international standards, and will work together with TACT Taiwan Cellular Medicine Association to convey industry issues to the government; and collaborate with Taipei Medical University to develop new products With technology, and through the CellTech Innovation Accelerator, we assist the development of new companies and work together to create a new situation in cell medicine. For Taiwan’s new technology companies or teams such as cell therapy, gene therapy and exosomes, we help them find industry experts, partners, match industry resources, expand international cooperation and export opportunities, etc., so that new technology teams can start at an early stage Connect with the international market and improve the production and supply chain of emerging biotechnology products.
Settled in Zhubei Biomedical Park to expand factory and develop cell therapy
In addition to cooperating with international companies, Qixin Technology also cooperates with Taiwan Ministry of Health and Welfare, Food and Drug Administration, Taiwan Centers for Disease Control, local health bureaus, Academia Sinica, consortiums, medical centers, international benchmark pharmaceutical companies, The local supply chain role of authoritative inspection and other institutions protects human health through complete one-stop services. In order to solve the problem of a wide and diverse range of microbial testing, Qixin Technology has combined its own brand CMP since 2007 to build a complete microbial testing product portfolio, specifically targeting three major areas - medical infectious disease diagnosis and biopharmaceutical quality control. and food safety, etc., and designed a one-stop solution to meet the four major needs of providing diagnosis, product compliance with regulations, high-throughput automatic analysis, and shortening inspection time. Especially starting from this year (2023), the Taipei factory has introduced the latest QMS (Quality Management Systems) management system. At the same time, it has invested 150 million to enter the Zhubei Biomedical Park, expand the PIC/S GMP Zhubei factory, and focus on establishing complete cell therapy and CDMO supply chain, within two years we will build a biological safety and efficacy testing service laboratory for cell and gene therapy, and within five years we will build a complete supply chain for the cell industry to achieve the sustainable development and growth of regenerative medicine and precision medicine.
Sustainable ESG management to build supply chain in Asia-Pacific region
Cai Yueting, general manager of Qixin Technology Company, which has just won the “2023 Outstanding Biotechnology Industry - Gold Award” and “Entrepreneurship Model Award”, said that in addition to focusing on the development of emerging biotech supply chains, Qixin will also assist Taiwan’s biotech and pharmaceutical industry. Going global, we are also fully committed to promoting various ESG indicators and long-term sustainable development, and are expected to complete public launch in Taiwan in 2025, provide more complete solutions for Taiwan’s biotech and pharmaceutical industry, and build a supply chain in the Asia-Pacific region. We look forward to allowing the world to recognize the quality, value and services of Taiwan’s biotech and pharmaceutical field, allowing Taiwan to shine and become the most trustworthy partner in the world.
